The US AI in Genomics Market is expected to grow at a CAGR of 33.6%, reaching a market size of USD 5,342.4 million in 2031 from USD 1,256.4 million in 2026.
The US Artificial Intelligence (AI) in Genomics Market comprises the software, services, and computational platforms that leverage machine learning and deep learning to analyze, interpret, and derive actionable insights from complex genomic and multiomic data. AI’s central function is to transform the massive, noisy datasets generated by Next-Generation Sequencing (NGS) into biologically and clinically meaningful findings, significantly accelerating the pace of drug discovery, precision medicine, and disease diagnosis. The convergence of computational advancements (particularly GPU-accelerated computing) and sequencing cost compression has established AI as a non-negotiable component of modern genomics research. This market is shifting from simply automating repetitive analysis tasks to using sophisticated foundation models to decode fundamental RNA and protein biology, establishing the US as a global epicenter for AI-driven biological discovery.
Growth Drivers
The exponential growth of genomic and multiomic data is the primary driver, catalyzed by lower sequencing costs, which directly creates demand for scalable AI software. Human analysts cannot process the billions of data points generated by population-scale sequencing projects; consequently, pharmaceutical and biotech companies must implement AI for efficient variant calling, gene annotation, and pathway analysis. Second, the proven success of AI in decoding complex biological structures, such as the development of predictive protein folding models, validates AI's capacity to accelerate the most intractable R&D problems. This demonstrable success drives direct demand for AI tools in the Drug Discovery and Development application segment by offering unprecedented speed and accuracy in target identification and drug optimization. Lastly, increased federal funding for biomedical AI projects, including those from the NSF focused on the intersection of AI and biological systems, mandates that academic and research institutes purchase commercial AI-based analytical Services to comply with project mandates and efficiently process grant-funded data.
Challenges and Opportunities
The main constraint facing the market is the lack of standardized, high-quality, and unbiased training datasets for clinical AI models, particularly for rare genetic conditions. Model bias and data heterogeneity limit the generalizability and trustworthiness of diagnostic AI tools, presenting a critical headwind. However, this challenge creates a vast opportunity: mandatory demand for federated learning and secure multi-institutional data analysis protocols (Offered as Services) that allow models to be trained on diverse datasets without compromising patient privacy or proprietary information. Another challenge is the "black box" nature of deep learning models, which hinders clinical adoption due to a lack of transparency. This opacity drives an opportunity for specialized Software Tools that incorporate explainable AI (XAI) techniques. Demand is therefore shifting toward tools that can provide a clear, interpretable rationale for genomic predictions, strengthening clinical trust and facilitating regulatory review.
Supply Chain Analysis
The AI in Genomics market's supply chain is fundamentally bifurcated into two critical, highly consolidated tiers. The first tier is the data generation hub, dominated by large sequencing hardware manufacturers, many based in the US (e.g., Illumina), which create the raw genomic data. The second, and more crucial, tier is the computational infrastructure layer, controlled by hyperscale cloud providers (e.g., AWS, Azure, Google Cloud) and hardware vendors like NVIDIA, which supply the powerful GPUs and specialized AI software frameworks (e.g., NVIDIA Clara suite) required for processing and model training. Logistical complexity is not physical but digital and regulatory, centered on the movement and storage of massive, sensitive patient data across secure cloud environments while maintaining compliance with HIPAA. This structural dependency on accelerated computing for all deep learning tasks makes the market highly sensitive to the availability and pricing of high-end computational resources. Moreover, tariffs on imported specialized sequencing equipment and high-performance computing (HPC) hardware increase the cost of Research infrastructure for US labs, thereby slowing the adoption of large-scale genomic AI Software.
Government Regulations:
Key US regulations and governmental guidance are shaping the market by establishing requirements for the clinical application and ethical use of AI-derived genomic insights, creating direct demand for compliant solutions.
Jurisdiction | Key Regulation / Agency | Market Impact Analysis |
|---|---|---|
Federal | FDA Draft Guidance: Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products (Jan 2025) | This guidance increases the demand for AI Services that provide robust data governance, clear documentation of model version control, and continuous monitoring of AI algorithms used in drug development pipelines to meet regulatory submission standards. |
Federal | Health Insurance Portability and Accountability Act (HIPAA) | HIPAA mandates strict protection for patient health information, including genomic data. This regulation creates compulsory demand for Software Tools and Services that integrate de-identification, anonymization, and secure data access protocols (e.g., secure multi-party computation) for AI model training and data sharing across research institutions. |
Federal | National Institutes of Health (NIH) Data Management and Sharing (DMS) Policy | The NIH DMS policy requires grant recipients to maximize the sharing of scientific data. This drives demand for AI Software that facilitates the efficient and compliant processing, curation, and cataloging of large genomic datasets, ensuring that AI research outcomes are reproducible and accessible to the wider scientific community. |
By Application: Drug Discovery and Development
The Drug Discovery and Development application segment experiences immense demand for AI, driven by the existential economic pressure to reduce the high failure rate and prolonged timelines of therapeutic R&D. Traditional methods for identifying novel drug targets, understanding disease mechanisms, and optimizing compound design are slow and prohibitively expensive. AI Software and Services directly address this by performing tasks such as causal disease trajectory mapping, high-throughput virtual screening, and predictive modeling of compound-target interactions. The ability of AI to rapidly analyze millions of genomic, proteomic, and clinical data points to pinpoint the most actionable biological targets, as demonstrated by partnerships between pharmaceutical giants and AI-first TechBio companies, creates new, high-value demand. AI fundamentally converts the time and cost barrier of drug discovery into a data and compute optimization problem, directly channeling investment into AI solutions.
By End-User: Pharmaceutical and Biotechnology Companies
Pharmaceutical and Biotechnology Companies are the most capital-intensive segment, and their demand for AI in genomics is driven by the strategic imperative to establish a proprietary, data-centric competitive advantage. These enterprises require sophisticated, often customized Software Tools and Services to integrate AI deep within their internal data pipelines for target identification, biomarker discovery, and clinical trial stratification. Their demand is specifically focused on scalable solutions that can manage their vast proprietary clinical and sequencing datasets, and proprietary foundation models like those being developed by Deep Genomics. Unlike academic groups, pharma's investment in AI is tied to measurable commercial outcomes, such as accelerating an investigational drug into the clinic or identifying patient populations most likely to respond to a specific therapy, thereby creating focused demand for precision medicine AI tools.
The competitive landscape is characterized by a dynamic interplay between established life science instrument giants, specialized AI-first startups, and major computational platform providers. Success is increasingly defined by the ability to combine proprietary, high-quality genomic data with sophisticated AI models.
Illumina
Illumina maintains a foundational strategic position by dominating the genomic data generation market. Recognizing the shift to interpretation, the company is actively moving into the AI analysis space, confirming this with the launch of BioInsight, a new business unit focused on developing data assets, software, and AI tools. Illumina’s strategy is to leverage its unparalleled data stream and massive install base to generate demand for its integrated AI Software platforms, making the transition from raw sequencing data to AI-driven biological insight seamless. Key products like DRAGEN (which includes AI-enhanced variant calling) and the focus on multiomic data aggregation demonstrate its commitment to monetizing data analysis, not just sequencing hardware.
NVIDIA Corporation
NVIDIA’s strategic positioning is as the foundational computing layer for all advanced AI in genomics. It accelerates the entire R&D pipeline by supplying the powerful GPUs and the domain-specific software stack, NVIDIA Clara, which includes tools for genomics analysis and computational drug discovery. The company does not generate genomic data but creates a mandatory demand for its high-performance hardware and software by making them indispensable for training and deploying large-scale deep learning models. Their verifiable collaborations, such as the one with Deepcell (January 2024), aim to co-develop new uses for generative AI in single-cell research, ensuring that their platforms remain central to cutting-edge genomic discoveries.
Deep Genomics
Deep Genomics is a prime example of an AI-first TechBio company whose strategy is to pioneer a new path for genomic medicines by building an AI foundation model platform for decoding RNA biology. Their focus on the Software and Services offering for Drug Discovery and Development is highlighted by the expansion of their foundation model platform. Deep Genomics drives demand by offering a verifiable, differentiated platform that accelerates the discovery and design of targeted RNA therapeutics by accurately predicting gene regulation, a capability that directly addresses a major bottleneck in pharmaceutical R&D.
October 2025: Illumina Launches BioInsight Business
Illumina, Inc. announced the launch of BioInsight, a new business unit focused on developing data assets, software, and AI solutions to accelerate life science discoveries. This product launch solidifies the company’s transition from a hardware focus to a data and AI services model. It significantly increases competition in the Software Tools and Services segments by bringing a major sequencing incumbent's resources directly into the AI-driven interpretation space, directly meeting industry demand for larger-scale multiomic data analysis.
June 2025: Illumina Announces Acquisition of SomaLogic
Illumina announced an agreement to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy. This merger and acquisition event creates an expanded product portfolio that combines high-throughput sequencing with advanced proteomics technology. The integration immediately increases the demand for AI Software capable of processing and interpreting multimodal (genomic and proteomic) data simultaneously, which is crucial for advancing precision medicine and drug target identification.
May 2025: Deep Genomics Expands AI Foundation Model Platform with REPRESS Model
Deep Genomics announced the latest addition to its AI foundation model platform, the REPRESS model, which accurately predicts microRNA (miRNA) binding and mRNA degradation directly from RNA sequences. This product launch directly accelerates the discovery of disease mechanisms and the design of targeted RNA therapeutics. The new model creates focused demand for high-level AI Software and Services among pharmaceutical and biotechnology companies looking to leverage unprecedented insight into gene regulation for their drug pipelines.
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 1,256.4 million |
| Total Market Size in 2031 | USD 5,342.4 million |
| Forecast Unit | Million |
| Growth Rate | 33.6% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Technology, Deployment, End-User Industry |
| Companies |
|
By Offering
Software
Services
By Application
Precision medicine
Diagnosis and prognosis
Drug discovery and development
Agriculture and animal breeding
Others
By End-User
Pharmaceutical and biotechnology companies
Academic and research institutes
Hospitals and diagnostic centers
Others